WO2003068170A3 - Enzyme treatment of foodstuffs for celiac sprue - Google Patents

Enzyme treatment of foodstuffs for celiac sprue Download PDF

Info

Publication number
WO2003068170A3
WO2003068170A3 PCT/US2003/004743 US0304743W WO03068170A3 WO 2003068170 A3 WO2003068170 A3 WO 2003068170A3 US 0304743 W US0304743 W US 0304743W WO 03068170 A3 WO03068170 A3 WO 03068170A3
Authority
WO
WIPO (PCT)
Prior art keywords
foodstuffs
enzyme treatment
celiac sprue
celiac
gluten
Prior art date
Application number
PCT/US2003/004743
Other languages
French (fr)
Other versions
WO2003068170A2 (en
Inventor
Felix Hausch
Gary Gray
Lu Shan
Chaitan Khosla
Original Assignee
Univ Leland Stanford Junior
Felix Hausch
Gary Gray
Lu Shan
Chaitan Khosla
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27739509&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2003068170(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to ES03711089.7T priority Critical patent/ES2361993T5/en
Priority to DK03711089.7T priority patent/DK1572127T4/en
Priority to EP11177678.7A priority patent/EP2409711B1/en
Priority to CA2475972A priority patent/CA2475972C/en
Priority to EP03711089.7A priority patent/EP1572127B2/en
Application filed by Univ Leland Stanford Junior, Felix Hausch, Gary Gray, Lu Shan, Chaitan Khosla filed Critical Univ Leland Stanford Junior
Priority to DE60336754T priority patent/DE60336754D1/en
Priority to AT03711089T priority patent/ATE505201T1/en
Priority to AU2003215272A priority patent/AU2003215272B2/en
Publication of WO2003068170A2 publication Critical patent/WO2003068170A2/en
Priority to AU2008202964A priority patent/AU2008202964B2/en
Publication of WO2003068170A3 publication Critical patent/WO2003068170A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/06—Enzymes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/16—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from plants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/14—Dipeptidyl-peptidases and tripeptidyl-peptidases (3.4.14)
    • C12Y304/14005—Dipeptidyl-peptidase IV (3.4.14.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/15—Peptidyl-dipeptidases (3.4.15)
    • C12Y304/15001—Peptidyl-dipeptidase A (3.4.15.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21026—Prolyl oligopeptidase (3.4.21.26), i.e. proline-specific endopeptidase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders
    • G01N2800/202—Dermatitis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Polymers & Plastics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)

Abstract

Administering an effective dose of glutenase to a Celiac or dermatitis herpetiformis patient reduces levels of toxic gluten oligopeptides, thereby attenuating or eliminating the damaging effects of gluten.
PCT/US2003/004743 2002-02-14 2003-02-14 Enzyme treatment of foodstuffs for celiac sprue WO2003068170A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
AU2003215272A AU2003215272B2 (en) 2002-02-14 2003-02-14 Enzyme treatment of foodstuffs for celiac sprue
DK03711089.7T DK1572127T4 (en) 2002-02-14 2003-02-14 Enzyme processing of foods for celiac disease
EP11177678.7A EP2409711B1 (en) 2002-02-14 2003-02-14 Enzyme treatment of foodstuffs for celiac sprue
CA2475972A CA2475972C (en) 2002-02-14 2003-02-14 Enzyme treatment of foodstuffs for celiac sprue
EP03711089.7A EP1572127B2 (en) 2002-02-14 2003-02-14 Enzyme treatment of foodstuffs for celiac sprue
ES03711089.7T ES2361993T5 (en) 2002-02-14 2003-02-14 Enzyme treatment of food products for celiac disease
DE60336754T DE60336754D1 (en) 2002-02-14 2003-02-14 ENZYM TREATMENT OF FOODS FOR CELIAC SPRUE
AT03711089T ATE505201T1 (en) 2002-02-14 2003-02-14 ENZYME TREATMENT OF FOODS FOR CELIAIC SPRAY
AU2008202964A AU2008202964B2 (en) 2002-02-14 2008-07-03 Enzyme treatment of foodstuffs for celiac sprue

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US35723802P 2002-02-14 2002-02-14
US60/357,238 2002-02-14
US38076102P 2002-05-14 2002-05-14
US60/380,761 2002-05-14
US39278202P 2002-06-28 2002-06-28
US60/392,782 2002-06-28
US42293302P 2002-10-31 2002-10-31
US60/422,933 2002-10-31
US42803302P 2002-11-20 2002-11-20
US60/428,033 2002-11-20
US43588102P 2002-12-20 2002-12-20
US60/435,881 2002-12-20

Publications (2)

Publication Number Publication Date
WO2003068170A2 WO2003068170A2 (en) 2003-08-21
WO2003068170A3 true WO2003068170A3 (en) 2008-07-03

Family

ID=27739509

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/004743 WO2003068170A2 (en) 2002-02-14 2003-02-14 Enzyme treatment of foodstuffs for celiac sprue

Country Status (9)

Country Link
US (8) US7303871B2 (en)
EP (3) EP2364718B1 (en)
AT (1) ATE505201T1 (en)
AU (1) AU2003215272B2 (en)
CA (1) CA2475972C (en)
DE (1) DE60336754D1 (en)
DK (2) DK2364718T3 (en)
ES (2) ES2706911T3 (en)
WO (1) WO2003068170A2 (en)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9923306D0 (en) * 1999-10-01 1999-12-08 Isis Innovation Diagnostic and therapeutic epitope, and transgenic plant
EP2364718B1 (en) 2002-02-14 2016-07-06 The Board of Trustees of the Leland Stanford Junior University Enzyme treatment of foodstuffs for celiac sprue
US7320788B2 (en) * 2002-02-14 2008-01-22 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for Celiac Sprue
US8143210B2 (en) * 2002-02-14 2012-03-27 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for celiac sprue
US7202216B2 (en) * 2002-05-14 2007-04-10 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
US7265093B2 (en) * 2002-05-14 2007-09-04 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for Celiac Sprue
EP1507549A4 (en) 2002-05-14 2009-07-01 Univ Leland Stanford Junior Drug therapy for celiac sprue
US7462688B2 (en) 2002-05-14 2008-12-09 The Board Of Trustees Of The Leland Stanford Junior University Peptides for diagnostic and therapeutic methods for celiac sprue
GB0212885D0 (en) * 2002-06-05 2002-07-17 Isis Innovation Therapeutic epitopes and uses thereof
DK1563300T3 (en) 2002-11-20 2012-07-23 Univ Leland Stanford Junior Diagnostic procedure for celiac disease
DK1663298T3 (en) * 2003-09-23 2019-10-14 Dsm Ip Assets Bv APPLICATION OF PROLINE-SPECIFIC ENDOPROTEAS FOR HYDROLYSE OF PEPTIDES AND PROTEINS
US7579313B2 (en) 2003-11-18 2009-08-25 The Board Of Trustees Of The Leland Stanford Junior University Transglutaminase inhibitors and methods of use thereof
US7534426B2 (en) 2004-04-26 2009-05-19 The Board Of Trustees Of The Leland Stanford Junior University Glutenase enzyme assays
US7563864B2 (en) 2004-04-26 2009-07-21 Celiac Sprue Research Foundation Prolyl endopeptidase mediated destruction of T cell epitopes in whole gluten
US7628985B2 (en) 2004-04-26 2009-12-08 The Board Of Regents Of The Leland Stanford Junior University Therapeutic enzyme formulations and uses thereof in celiac sprue and/or dermatitis herpetoformis
WO2005105129A2 (en) * 2004-04-28 2005-11-10 Btg International Limited Epitopes related to coeliac disease
AU2011247868B2 (en) * 2004-04-28 2014-05-22 Btg International Limited Epitopes related to coeliac disease
US10105437B2 (en) 2004-04-28 2018-10-23 Btg International Limited Epitopes related to coeliac disease
WO2006097949A1 (en) * 2005-03-16 2006-09-21 Actial Farmacêutica, Lda. Mixture of at least 6 species of lactic acid bacteria and/or bifidobacteria in the manufacture of sourdough
EP1949093A2 (en) * 2005-10-11 2008-07-30 Alvine Pharmaceuticals, Inc. Compositions and methods for enhanced gastrointestinal stability of oligopeptides and polypeptides
WO2007047303A2 (en) * 2005-10-12 2007-04-26 Alvine Pharmaceuticals, Inc. Pegylated glutenase polypeptides
WO2007053619A2 (en) * 2005-11-01 2007-05-10 Bio-Cat, Inc. A composition with a fungal (yeast) lipase and method for treating lipid malabsorption in cystic fibrous as well as people suffering from pancreatic lipase insufficiency
US7943328B1 (en) 2006-03-03 2011-05-17 Prometheus Laboratories Inc. Method and system for assisting in diagnosing irritable bowel syndrome
US8637325B2 (en) * 2009-02-16 2014-01-28 University Of Wyoming Method and apparatus for pyrolysis-induced cleavage in peptides and proteins
US20080085524A1 (en) 2006-08-15 2008-04-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
DE102007011515A1 (en) 2007-03-09 2008-09-11 Kampffmeyer Food Innovation Gmbh Treatment of diverse grain flours, to break down proteins causing celiac disease reaction, adds enzymes extracted from bran to flour product
US8778338B2 (en) 2007-03-16 2014-07-15 The Board Of Trustees Of The Leland Stanford Junior University Combination enzyme therapy for digestion of dietary gluten
WO2008115428A2 (en) * 2007-03-16 2008-09-25 The Board Of Trustees Of The Leland Stanford Junior University A scaleable manufacturing process for cysteine endoprotease b, isoform 2
US8980254B2 (en) * 2008-08-21 2015-03-17 Alvine Pharmaceuticals, Inc. Formulation for oral administration of proteins
NZ591940A (en) * 2008-10-10 2013-08-30 Alvine Pharmaceuticals Inc Dosage forms that facilitate rapid activation of zymogen
CN105079781B (en) 2008-11-30 2018-07-20 免疫桑特公司 Composition for treating chylous diarrhea and method
AU2010205890B2 (en) * 2009-01-15 2015-01-15 Glutagen Pty Ltd Compositions for the treatment of gluten intolerance and uses thereof
EP3309556B1 (en) 2009-06-25 2020-04-08 Prometheus Biosciences, Inc. Methods for diagnosing irritable bowel syndrome
US20120107847A1 (en) 2009-07-02 2012-05-03 Dsm Ip Assets B.V. Testing efficacy for celiac disease
US8685392B2 (en) 2009-10-07 2014-04-01 Trustees Of Boston University Rothia species glutamine endopeptidases and use thereof
CN102858795A (en) * 2010-02-02 2013-01-02 天野酶制品美国有限公司 Use of proteases for gluten intolerance
EP3604558B1 (en) 2010-02-17 2022-10-12 Gen-Probe Incorporated Compositions and methods to detect atopobium vaginae nucleic acid
WO2011112792A1 (en) * 2010-03-10 2011-09-15 IMMCO Diagnostics, Inc. Compositions and methods for determining celiac disease
AU2011238586A1 (en) * 2010-03-30 2012-11-08 Alvine Pharmaceuticals, Inc. Proteases for degrading gluten
WO2012006384A2 (en) * 2010-07-07 2012-01-12 Trustees Of Boston University Rothia species gluten-degrading enzymes and uses thereof
WO2012135646A2 (en) * 2011-03-30 2012-10-04 Alvine Pharmaceuticals, Inc. Proteases for degrading gluten
WO2012174127A1 (en) * 2011-06-17 2012-12-20 Alvine Pharmaceuticals, Inc. Proteases for degrading gluten
CN103997899B (en) 2011-06-20 2016-04-20 H.J.亨氏公司 Probiotic composition and method
WO2013016427A1 (en) 2011-07-25 2013-01-31 Alvine Pharmaceuticals, Inc. Methods and pharmaceutical compositions for treating celiac disease and gluten intolerance
ES2896489T3 (en) 2011-08-10 2022-02-24 Univ Washington Through Its Center For Commercialization Compositions and procedures for the treatment of celiac sprue disease
CN104039345B (en) 2011-12-06 2016-11-09 英萨博瑞克寻找生命基础研究所 From actinomyces unwrapping wire different Teichaic acid Pseudomonas (Actinoallomurus) can be at the new protease of acid pH hydrolyzed gluten peptide and albumen
DK2861242T3 (en) * 2012-06-18 2018-10-29 Heinz Co Brands H J Llc GLUTEN RELATED DISORDERS
ITRM20120468A1 (en) * 2012-10-02 2014-04-03 Uni Degli Studi Di Foggia METHOD FOR DETOXIFICATION OF GLUTEN PROTEINS FROM CEREALS GRAIN
US9005610B2 (en) 2012-11-21 2015-04-14 Nepetx, Llc Treatment of gluten intolerance and related conditions
WO2014116871A1 (en) 2013-01-23 2014-07-31 Alvine Pharmaceuticals, Inc. Methods and pharmaceutical compositions for treating celiac disease and gluten intolerance
US20160041148A1 (en) * 2013-03-14 2016-02-11 Immusant,Inc. Placebo-controlled gluten challenge method
SI3004340T1 (en) 2013-03-15 2020-11-30 Codexis, Inc., Treatment of gluten intolerance and related conditions
PT2994150T (en) 2013-05-10 2019-06-14 Heinz Co Brands H J Llc Probiotics and methods of use
JP6517204B2 (en) 2013-08-14 2019-05-22 ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャリゼーション Compositions and methods for treating celiac sprue disease
EP3043812A1 (en) 2013-09-10 2016-07-20 Immusant Inc. Dosage of a gluten peptide composition
EP2883458A1 (en) * 2013-12-11 2015-06-17 DSM IP Assets B.V. Medicament and method for treating innate immune response diseases
WO2015177153A1 (en) 2014-05-19 2015-11-26 Dsm Ip Assets B.V. Proline-specific endoprotease
MX2016015036A (en) 2014-05-19 2017-05-02 Dsm Ip Assets Bv Proline-specific endoprotease.
WO2015177152A1 (en) 2014-05-19 2015-11-26 Dsm Ip Assets B.V. Proline-specific endoprotease
US20160022785A1 (en) 2014-06-16 2016-01-28 Nepetx, Llc Compositions and methods for treating gluten intolerance and disorders arising therefrom
CA2962933A1 (en) 2014-09-29 2016-04-07 Immusant, Inc. Use of hla genetic status to assess or select treatment of celiac disease
US20160339086A1 (en) * 2015-05-19 2016-11-24 Suzy Cohen Compositions and methods for treating thyroid disease
EP3302518A1 (en) 2015-06-08 2018-04-11 University of Washington Compositions and methods for treating celiac sprue disease
JP2019504011A (en) 2015-12-16 2019-02-14 ネプエトゥクス，エルエルシー Compositions and methods for treating gluten intolerance and disorders caused thereby
ITUB20159442A1 (en) 2015-12-17 2017-06-17 New Gluten World Srl METHOD OF DETOXIFICATION OF GLUTEN PROTEINS FROM THE GRAINS OF CEREALS AND RELATED USES IN THE MEDICAL FIELD
US10702590B2 (en) 2016-04-12 2020-07-07 Script Essentials, Llc Compositions and methods for treating thyroid disease
US20190307860A1 (en) 2016-11-23 2019-10-10 Immunogenics Llc Latiglutenase (alv003) for use in the treatment of symptomatic celiac disease, gluten intolerance or gluten sensitivity
EP3893669A1 (en) 2018-12-13 2021-10-20 DSM IP Assets B.V. Umami flavour composition
US20220364069A1 (en) 2019-07-25 2022-11-17 Nemysis Limited Method for the production of an enzymatic composition comprising a recombinant endopeptidase
IT201900012942A1 (en) 2019-07-25 2021-01-25 Nemysis Ltd METHOD FOR THE PRODUCTION OF AN ENZYMATIC COMPOSITION INCLUDING A RECOMBINANT ENDOPEPTIDASE
WO2021254943A1 (en) 2020-06-17 2021-12-23 Dsm Ip Assets B.V. Umami flavour composition

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994026774A1 (en) * 1993-05-19 1994-11-24 Cytel Corporation Novel treatments for allergic diseases
EP0905518A1 (en) * 1997-09-23 1999-03-31 Academisch Ziekenhuis Leiden Peptides specific for gluten-sensitive T-cells and use thereof

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7414128A (en) 1973-10-31 1975-05-02 James Joseph Phelan PROCESS FOR THE DETOXIFICATION OF GLUTEN.
GB1509866A (en) 1975-06-10 1978-05-04 Johnson & Johnson Enteric coated digestive enzyme compositions
US4203967A (en) 1977-01-13 1980-05-20 Hoffmann-La Roche Inc. Diagnostic test for malabsorption
US4562003A (en) * 1984-10-26 1985-12-31 California Biotechnology, Inc. Monoclonal antibodies against alveolar surfactant protein
US4912120A (en) 1986-03-14 1990-03-27 Syntex (U.S.A.) Inc. 3,5-substituted 4,5-dihydroisoxazoles as transglutaminase inhibitors
HU199809B (en) 1986-03-14 1990-03-28 Syntex Inc Process for producing aminomethyl-4,5-dihydroisoxazole derivatives and pharmaceutical compositions comprising same
US4929630A (en) * 1986-03-14 1990-05-29 Syntex (U.S.A.) Inc. Transglutaminase inhibitors
DD262999A1 (en) 1987-07-27 1988-12-21 Adw Ddr METHOD FOR PRODUCING A DIETETIC FOR ZOELIAKIE AND SPRUCE BARRIER
US5208021A (en) * 1987-10-05 1993-05-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method of preparing diphtheria immunotoxins
US5372933A (en) * 1988-10-03 1994-12-13 The Scripps Research Institute Polypeptides that mimic receptor-induced binding sites, and methods of using same
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US5811098A (en) * 1992-11-24 1998-09-22 Bristol-Myers Squibb Company Antibodies to HER4, human receptor tyrosine kinase
GB9225021D0 (en) * 1992-11-30 1993-01-20 Sandoz Ltd Organic compounds
US6197356B1 (en) * 1993-08-03 2001-03-06 Immunopath Profile, Inc. Process for preparing hypoallergenic foods
US5663304A (en) * 1993-08-20 1997-09-02 Genentech, Inc. Refolding of misfolded insulin-like growth factor-I
AU1739395A (en) * 1994-02-07 1995-08-21 United States Of America, As Represented By The Secretary Of Agriculture, The Detection of wheat that has experienced elevated temperatures during the grain filling period
WO1996010034A2 (en) 1994-09-29 1996-04-04 Merck & Co., Inc. Thiol-free inhibitors of farnesyl-protein transferase
US5834428A (en) 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
GB9509336D0 (en) * 1995-05-09 1995-06-28 Dynal As Chemical method
US7048906B2 (en) * 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US20020018763A1 (en) * 1995-05-24 2002-02-14 Kriszkina M. Zsebo A method of stimulating growth of stromal cells with stem cell factor (scf) polypeptides
DE19630557C2 (en) 1996-07-18 1998-07-02 Schuppan Detlef Priv Doz Dr Dr Method for the detection of antibodies from body fluids by an immune reaction with tissue transglutaminase (tTG) as well as the use of tTG in diagnosis and therapy
US7696338B2 (en) * 1995-10-30 2010-04-13 The United States Of America As Represented By The Department Of Health And Human Services Immunotoxin fusion proteins and means for expression thereof
US5716794A (en) * 1996-03-29 1998-02-10 Xybernaut Corporation Celiac antigen
US5750104A (en) 1996-05-29 1998-05-12 Digestive Care Inc. High buffer-containing enteric coating digestive enzyme bile acid compositions and method of treating digestive disorders therewith
DE69723163T2 (en) * 1996-07-24 2004-05-19 Antonio Picarelli Method and test kit for in vitro confirmation of the diagnosis of abdominal disease
US6225290B1 (en) 1996-09-19 2001-05-01 The Regents Of The University Of California Systemic gene therapy by intestinal cell transformation
US5912327A (en) * 1996-09-30 1999-06-15 Human Genome Sciences, Inc. Method of purifying chemokines from inclusion bodies
US6635462B1 (en) * 1997-05-12 2003-10-21 Phoenix Pharmacologies, Inc. Mutated form of arginine deiminase
US6008027A (en) 1997-07-17 1999-12-28 Langner; Bruce J. Enteric polymer coated capsule containing dried bacterial culture for supplying lactase
US20020052026A1 (en) * 1997-10-08 2002-05-02 Steven M. Vicik Methods of refolding proteins
EA003190B1 (en) 1997-12-31 2003-02-27 Пфайзер Продактс Инк. Aryl fused azapolycyclic compounds
AU3596199A (en) 1998-05-06 1999-11-23 Kobenhavns Universitet Treatment of celiac disease
US6201695B1 (en) * 1998-10-26 2001-03-13 Micron Technology, Inc. Heat sink for chip stacking applications
WO2000033077A1 (en) * 1998-12-04 2000-06-08 Barnes-Jewish Hospital Cell matrix plaques of initial bone formation
ATE494388T1 (en) 1999-01-13 2011-01-15 Univ New York State Res Found NEW METHOD FOR CREATING PROTEIN KINASE INHIBITORS
GB9912350D0 (en) * 1999-05-26 1999-07-28 European Molecular Biology Lab Embl Modified cytokine
US6962989B1 (en) * 1999-07-08 2005-11-08 Basf Aktiengesellschaft Corynebacterium glutamicum genes encoding novel proteins
US6395889B1 (en) * 1999-09-09 2002-05-28 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding human protease homologs
GB9923306D0 (en) * 1999-10-01 1999-12-08 Isis Innovation Diagnostic and therapeutic epitope, and transgenic plant
WO2001029078A2 (en) * 1999-10-15 2001-04-26 Heska Corporation Method for production and use of mite group 1 proteins
US6492498B1 (en) * 1999-11-15 2002-12-10 Regents Of The University Of Minnesota Multimeric immunotoxins
US6667160B2 (en) 2000-03-15 2003-12-23 Kenneth D. Fine Method for diagnosing immunologic food sensitivity
US6642036B2 (en) * 2000-07-07 2003-11-04 E. I. Du Pont De Nemours And Company Sinapoylglucose:malate sinapoyltransferase form malate conjugates from benozic acid glucosides
US6833447B1 (en) * 2000-07-10 2004-12-21 Monsanto Technology, Llc Myxococcus xanthus genome sequences and uses thereof
EP1201136A1 (en) * 2000-10-31 2002-05-02 Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO Food grade transglutaminase inhibitor and uses thereof
AU1608902A (en) * 2000-12-07 2002-06-18 Dsm Nv Protein hydrolysates enriched in peptides having a carboxy terminal proline residue
PT1326957E (en) * 2000-12-07 2004-09-30 Dsm Ip Assets Bv METHOD FOR THE PREVENTION OR REDUCTION OF FLAVORING IN BEVERAGES
US20040116663A1 (en) * 2001-01-16 2004-06-17 Soren Buus Method for refolding of proteins
US7442370B2 (en) * 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
US20040241161A1 (en) * 2001-04-12 2004-12-02 Drijfhout Jan Wouter Methods and means for use of hla-dq restricted t-cell receptors and hla-dq-binding prolamine-derived peptides
US6645739B2 (en) * 2001-07-26 2003-11-11 Phoenix Pharmacologies, Inc. Yeast expression systems, methods of producing polypeptides in yeast, and compositions relating to same
NO20015814D0 (en) 2001-11-28 2001-11-28 Amersham Health As Metal complex compounds
EP1332760A1 (en) * 2002-02-04 2003-08-06 Academisch Ziekenhuis Leiden Novel epitopes for celiac disease and autoimmune diseases, methods for detecting those and novel non-antigenic food compounds
US7320788B2 (en) * 2002-02-14 2008-01-22 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for Celiac Sprue
EP2364718B1 (en) * 2002-02-14 2016-07-06 The Board of Trustees of the Leland Stanford Junior University Enzyme treatment of foodstuffs for celiac sprue
US20030224476A1 (en) * 2002-03-01 2003-12-04 Szu-Yi Chou Method of producing transglutaminase reactive compound
US7462688B2 (en) 2002-05-14 2008-12-09 The Board Of Trustees Of The Leland Stanford Junior University Peptides for diagnostic and therapeutic methods for celiac sprue
EP1507549A4 (en) 2002-05-14 2009-07-01 Univ Leland Stanford Junior Drug therapy for celiac sprue
US7202216B2 (en) * 2002-05-14 2007-04-10 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
US7265093B2 (en) * 2002-05-14 2007-09-04 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for Celiac Sprue
US6903246B2 (en) * 2002-05-28 2005-06-07 The Regents Of The University Of California Dehydroascorbate reductase (“DHAR”) genes from Triticum aestivum and their use to modulate ascorbic acid levels in plants
GB0212885D0 (en) 2002-06-05 2002-07-17 Isis Innovation Therapeutic epitopes and uses thereof
DK1563300T3 (en) 2002-11-20 2012-07-23 Univ Leland Stanford Junior Diagnostic procedure for celiac disease
CN1311076C (en) * 2003-04-16 2007-04-18 普罗特奥姆技术公司 Method for producing recombinaton urokinase
US20050049064A1 (en) * 2003-09-02 2005-03-03 Gagne Robert M. Golf training apparatus
US7579313B2 (en) * 2003-11-18 2009-08-25 The Board Of Trustees Of The Leland Stanford Junior University Transglutaminase inhibitors and methods of use thereof
US20050227920A1 (en) * 2003-12-11 2005-10-13 Xinli Lin Methods for production of recombinant vascular endothelial cell growth inhibitor
US7534426B2 (en) * 2004-04-26 2009-05-19 The Board Of Trustees Of The Leland Stanford Junior University Glutenase enzyme assays
US7521427B2 (en) * 2004-11-09 2009-04-21 Georgia Tech Research Corporation Peptidyl allyl sulfones
EP1949093A2 (en) * 2005-10-11 2008-07-30 Alvine Pharmaceuticals, Inc. Compositions and methods for enhanced gastrointestinal stability of oligopeptides and polypeptides
WO2007047303A2 (en) * 2005-10-12 2007-04-26 Alvine Pharmaceuticals, Inc. Pegylated glutenase polypeptides
EP1954285A2 (en) * 2005-10-25 2008-08-13 Alvine Pharmaceuticals, Inc. Transglutaminase inhibitors and methods of use thereof
US20070099238A1 (en) * 2005-10-31 2007-05-03 Sigalas Mihail M Enhancement of emission using metal coated dielectric nanoparticles
EP1845103B1 (en) * 2006-04-10 2015-02-25 Boehringer Ingelheim RCV GmbH & Co KG Method for refolding a protein
WO2008115428A2 (en) 2007-03-16 2008-09-25 The Board Of Trustees Of The Leland Stanford Junior University A scaleable manufacturing process for cysteine endoprotease b, isoform 2
US8778338B2 (en) 2007-03-16 2014-07-15 The Board Of Trustees Of The Leland Stanford Junior University Combination enzyme therapy for digestion of dietary gluten
US8980254B2 (en) 2008-08-21 2015-03-17 Alvine Pharmaceuticals, Inc. Formulation for oral administration of proteins
NZ591940A (en) 2008-10-10 2013-08-30 Alvine Pharmaceuticals Inc Dosage forms that facilitate rapid activation of zymogen

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994026774A1 (en) * 1993-05-19 1994-11-24 Cytel Corporation Novel treatments for allergic diseases
EP0905518A1 (en) * 1997-09-23 1999-03-31 Academisch Ziekenhuis Leiden Peptides specific for gluten-sensitive T-cells and use thereof

Also Published As

Publication number Publication date
US20080145356A1 (en) 2008-06-19
EP2364718A1 (en) 2011-09-14
ES2706911T3 (en) 2019-04-01
DK2364718T3 (en) 2016-10-03
DK1572127T3 (en) 2011-07-25
CA2475972A1 (en) 2003-08-21
US20110293724A1 (en) 2011-12-01
US7910541B2 (en) 2011-03-22
US20080213427A1 (en) 2008-09-04
EP1572127B1 (en) 2011-04-13
AU2003215272B2 (en) 2008-04-03
ES2361993T5 (en) 2014-12-09
EP1572127B2 (en) 2014-10-29
US20090280555A1 (en) 2009-11-12
ATE505201T1 (en) 2011-04-15
US7928056B2 (en) 2011-04-19
AU2003215272A1 (en) 2003-09-04
US7943312B2 (en) 2011-05-17
US20080213822A1 (en) 2008-09-04
ES2361993T3 (en) 2011-06-27
DE60336754D1 (en) 2011-05-26
EP2409711A1 (en) 2012-01-25
WO2003068170A2 (en) 2003-08-21
CA2475972C (en) 2017-07-11
EP2409711B1 (en) 2018-11-21
EP2364718B1 (en) 2016-07-06
US7923532B2 (en) 2011-04-12
US20030215438A1 (en) 2003-11-20
US20170119860A1 (en) 2017-05-04
US7303871B2 (en) 2007-12-04
EP1572127A4 (en) 2009-03-18
US8962545B2 (en) 2015-02-24
EP1572127A2 (en) 2005-09-14
US20080213245A1 (en) 2008-09-04
DK1572127T4 (en) 2014-11-24

Similar Documents

Publication Publication Date Title
WO2003068170A3 (en) Enzyme treatment of foodstuffs for celiac sprue
WO2003096979A3 (en) Drug therapy for celiac sprue
WO2007030567A3 (en) Pparactive compounds
WO2003101397A3 (en) Tetravalent dengue vaccines
EP0919622A3 (en) Surface expression of enzyme in gene directed prodrug therapy
AU2003274071A1 (en) Dosage form that is safeguarded from abuse
WO2004010937A3 (en) Method of treating cancer
WO2005030200A8 (en) Remedy for autoimmune diseases
WO2006085115A3 (en) Therapeutic uses of tomato extracts
WO2007081878A3 (en) Indoleamine 2,3-dioxygenase pathways in the generation of regulatory t cells
WO2009031606A1 (en) Therapeutic and prophylactic agents for arthritis
WO2007056301A3 (en) Antibody therapy for treatment of diseases associated with gluten intolerance
WO2004064735A3 (en) Treatment of benign prostatic hyperplasia
MXPA02012249A (en) Peptides, compositions and methods for the treatment of burkholderia cepacia.
AU2003229284A1 (en) Active substances for the treatment, diagnosis and prophylaxis of diseases in which abnormal protein structures occur
AU4651700A (en) Salts of aminoimidazole carboxamide useful in the prevention and treatment of liver diseases
WO2004108062A3 (en) Prophylaxis and/or treatment of portal hypertension
TW200505408A (en) Agent for preventing and/or treating tissue disruption-accompanied diseases
WO2004080477A8 (en) Aplidine for multiple myeloma treatment
WO2007031853A3 (en) Therapeutic combination of hamlet and a hdac inhibitor to treat cancer
WO2005005382A3 (en) Compounds, compositions and methods
AU2002317259A1 (en) Pharmaceutical composition for diagnosis, prevention or treatment of a tumorous state, comprising a modulator of the actin polymerisation state
WO2006004774A3 (en) Laulimalide analogues as therapeutic agents
EP1396264A4 (en) Agents for relieving eye controlling function error
WO2004019965A3 (en) Thymus-based tolerogenic approaches for type i diabetes.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2475972

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003215272

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2003711089

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003711089

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP